Healthcare player, Cadila Healthcare (Zydus Cadila) informed that the company has received the final approval from the US drug regulator, USFDA to market Acyclovir Capsules USP, 200 mg.
The drug falls in the anti-viral segment and will be produced at the formulations manufacturing facility at SEZ, Ahmedabad.
The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare shares traded nearly flat on the Bombay Stock Exchange (BSE) on Tuesday with flat trade at Rs 318.60.